Biomea Fusion, Inc.
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
BMEA$0.55-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2025 | 2024 | |
| Operating Activities | ||
| Net loss | $(29,262) | $(39,061) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation expense | 468 | 420 |
| Non-cash operating lease expense | 766 | 999 |
| Stock-based compensation expense | 3,169 | 5,022 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,232 | (333) |
| Other assets | 2 | (1,236) |
| Accounts payable | (5,220) | (2,176) |
| Accrued expenses and other current liabilities | 4,022 | 3,836 |
| Operating lease liabilities | (844) | 499 |
| Net cash used in operating activities | (25,667) | (32,030) |
| Investing Activities | ||
| Purchase of property and equipment | — | (35) |
| Net cash used in investing activities | — | (35) |
| Financing Activities | ||
| Proceeds from issuances of common stock under ATM program | 3,257 | — |
| Payments of financing costs | (5) | — |
| Proceeds from stock option exercise | — | 116 |
| Net cash provided by financing activities | 3,252 | 116 |
| Net decrease in cash, cash equivalents, and restricted cash | (22,415) | (31,949) |
| Cash, cash equivalents, and restricted cash at the beginning of the period | 58,648 | 177,236 |
| Cash, cash equivalents, and restricted cash at the end of the period | $36,233 | $145,287 |
| Non-cash financing and investing activities: | ||
| Acquisition of property and equipment in accounts payable and accrued liabilities | $— | $34 |
| Financing costs included in accounts payable | $5 | $— |
| Reconciliation of cash and cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $35,864 | $144,918 |
| Restricted cash | 369 | 369 |
| Total cash and cash equivalents, and restricted cash | $36,233 | $145,287 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.